Spotlight: Potassium in Neuroendocrine Tumours (NETs)

Before you read this This information is designed to help you understand how vitamins and minerals work in the body and how certain NET-related factors might affect them. It is not a substitute for personalised medical advice. Every NET patient is different — tumour type, treatments, surgery, symptoms, and nutritional needs can vary widely. If you have concerns about vitamin levels, supplements, or symptoms, please speak with your NET clinical team. They can assess your individual situation and guide you safely.

Potassium is one of the most tightly regulated electrolytes in the body. Even small deviations can affect muscle strength, gut motility, and—critically—cardiac rhythm. For people living with neuroendocrine tumours (NETs), hypokalaemia (low potassium) is surprisingly common and often under‑recognised. This Spotlight explains why NET patients are vulnerable, how deficiency presents, and what clinicians look for when assessing and managing it.

What potassium does Potassium is the primary intracellular cation, essential for:

Resting membrane potential and nerve conduction
Muscle contraction and neuromuscular stability
Cardiac rhythm and repolarisation
Acid–base balance
Insulin‑mediated cellular uptake

Only around 2% of total body potassium is in the bloodstream, which means serum levels can change rapidly and dangerously.

Why NET patients are prone to hypokalaemia (low potassium)

Functional NETs with secretory diarrhoea

VIPoma (WDHA syndrome) causes profound watery diarrhoea, bicarbonate loss, and severe potassium depletion.
Serotonin‑secreting midgut NETs increase gut motility and stool output, driving chronic potassium loss.
Other hormone‑secreting NETs (e.g., somatostatinoma, gastrinoma, ectopic ACTH secreting (including Neuroendocrine Carcinoma where applicable), may contribute indirectly through diarrhoea or malabsorption.

Somatostatin analogues (SSAs)

SSAs reduce hormone‑driven diarrhoea but can also alter gastrointestinal motility and absorption. In patients with borderline intake or malabsorption, this can perpetuate mild electrolyte loss.

GI surgery and malabsorption

Ileal resection, short‑bowel states, or extensive small‑bowel disease reduce absorptive surface and increase stool losses.

Renal potassium wasting

Volume depletion from diarrhoea activates the renin–angiotensin–aldosterone system (RAAS). Aldosterone rises and the kidneys excrete more potassium. This means diarrhoea causes both gastrointestinal and renal potassium loss.

Medication‑related losses

Diuretics, insulin, beta‑agonists, and certain antifungals/antibiotics can worsen hypokalaemia.

How potassium is regulated

Renal control

The kidney is the main regulator of potassium balance. Aldosterone increases potassium secretion in the distal nephron. When NET‑related diarrhoea causes dehydration, aldosterone rises, worsening potassium loss.

GI balance

The colon can absorb or secrete potassium. In secretory diarrhoea (for example, VIPoma), colonic secretion increases and transit accelerates, leading to large faecal potassium losses.

Magnesium interplay

Magnesium deficiency impairs renal potassium reabsorption. If magnesium is low, potassium replacement often fails. Magnesium deficiency is common in NET patients and should be considered whenever hypokalaemia is persistent or difficult to correct

Symptoms NET patients may notice

Muscle weakness, cramps, heaviness in the legs
Difficulty climbing stairs or rising from a chair
Palpitations or irregular heartbeat
Fatigue and reduced exercise tolerance
In severe cases: paralysis or dangerous arrhythmias

Hypokalaemia below 2.5 mmol/L is a medical urgency and usually requires prompt assessment and treatment.

Risk levels in NET patients

Low risk – stable, non‑functional NETs; no diarrhoea; normal renal function.
Medium risk – intermittent diarrhoea; mild malabsorption; somatostatin analogue therapy.
High risk – VIPoma; severe carcinoid diarrhoea; ectopic ACTH related, short‑bowel syndrome; diuretic use.

Assessing potassium status

Serum potassium

The primary test, but results must be interpreted alongside magnesium, bicarbonate, and renal function.

ECG

Clinicians look for U waves, flattened T waves, ST‑segment depression, and arrhythmias in moderate to severe hypokalaemia.

Urinary potassium

Urinary potassium helps distinguish renal wasting (high urinary potassium in the setting of hypokalaemia) from predominantly gastrointestinal loss (low urinary potassium).

Clinical context

Frequency and volume of diarrhoea, presence of vomiting, medication list (including diuretics, insulin, beta‑agonists), hydration status, and magnesium levels are all important in NET patients.

Clinical management (NET‑specific)

Treat the underlying cause

VIPoma – somatostatin analogues, rehydration, and tumour‑directed therapy (surgery, systemic treatment) can dramatically reduce diarrhoea and potassium loss.
Carcinoid syndrome – optimise SSA dosing, consider additional anti‑diarrhoeal strategies, and evaluate for disease progression.

Replace potassium

Mild (3.0–3.4 mmol/L) – oral potassium supplements, dietary optimisation, and close monitoring.
Moderate (2.5–3.0 mmol/L) – oral plus intravenous replacement depending on symptoms, ECG changes, and ongoing losses.
Severe (<2.5 mmol/L) – urgent intravenous replacement with cardiac monitoring, correction of volume status and magnesium, and investigation for functional NET or other causes.

Correct magnesium and hydration

Magnesium must be checked and treated because low magnesium impairs potassium retention. Restoring intravascular volume reduces RAAS‑driven renal potassium loss.

Prevention

High‑risk NET patients benefit from regular monitoring of electrolytes, review of diuretic therapy, and early escalation when diarrhoea worsens or new symptoms appear.

Key takeaways

Hypokalaemia is common in NETs, especially functional tumours with secretory diarrhoea.
Magnesium deficiency frequently coexists and must be corrected for potassium to stabilise.
VIPoma is the most severe NET‑related cause of potassium loss and often presents with profound weakness and metabolic acidosis.
ECG monitoring is essential in moderate to severe hypokalaemia.
Treating the underlying NET and controlling diarrhoea can dramatically improve electrolyte stability.

References (2024–2026)

UK NHS Potassium
NIH Office of Dietary Supplements – Potassium Fact Sheet
NET Guidelines including NANETS and ENETS do not produce a specific guideline for Potassium but it is inferred in managing electrolytes in various publications, particularly in reference to functional tumours.
Merck Manual Professional Edition. Gastrointestinal Neuroendocrine Tumors and Carcinoid Syndrome. Updated 2024.
BMJ Best Practice. VIPoma—Symptoms, diagnosis and treatment. Evidence reviewed July 2026.
Stafl L, et al. Severe hypokalaemia and secretory diarrhoea secondary to a VIPoma. BMJ Case Reports. 2026.

Disclaimer: This Spotlight article is for information only and should not be considered medical advice. It is not a substitute for professional medical assessment, diagnosis, or treatment. Always consult your healthcare team about your individual situation. The content reflects current knowledge at the time of publication and may evolve as new evidence emerges.

Others in the Series

Iron – click here
Zinc – click here
Magnesium – click here

Disclaimer

I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.

Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional.

Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.